How Can Contractors Keep Up with a Construction Boom?

 

With the economic recovery holding strong, many industries are quickly rebounding, including construction. So, what’s the outlook post-COVID. Host Tyler Kern spoke with an industry expert on the subject, Jason Perez, CEO of YARDZ.

“2021 looks amazing for the industry. There are more projects but sometimes fewer people, so technology is filling the gap,” Perez said.

Perez noted the technological advancements in construction. “We’ve gone from blueprints to VR goggles that allow you to visualize a project before breaking ground.”
Using technology to accelerate projects is a big bucket. YARDZ offers a specialized software tool that allows companies and contractors to keep track of their managed and rented assets. That’s a process that often resides on a whiteboard.

“2021 looks amazing for the industry. There are more projects but sometimes fewer people, so technology is filling the gap.” – Jason Perez

“We had a customer with nine different whiteboards and labels, and he said, ‘I need a better way,’” Perez described. That better way comes from the company’s software, which he noted is really a product of their users. He continued, “We spoke to them early on to match their workflows and address their needs in the simplest way.”

The company’s commitment to optimizing processes and saving time can help them keep pace with the expected jump in project volume.

Perez addressed the roller coaster year of 2020. “Most projects didn’t get shut down. They kept moving, but there was a decline in RFPs. Then, at the end of 2020 and early 2021, a flood of RFPs appeared. 2022 is going to be a record-breaking year.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More